Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03478722 · ClinicalTrials.gov registry record
Muscle Protein Synthesis in Dialysis Patients
A clinical trial, sponsored by University of Illinois at Urbana-Champaign.
- Completed
- Registry status
- 16
- Enrollment target
NCT03478722: Completed study, sponsored by University of Illinois at Urbana-Champaign.
NCT03478722 is a clinical trial that has completed, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03478722 has completed, sponsored by University of Illinois at Urbana-Champaign.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
The most severe form of chronic renal failure is end-stage-renal-disease with maintenance hemodialysis (MHD) as the most common treatment strategy. MHD patients experience a number of metabolic and phenotypic derangements including skeletal muscle wasting. Previously, it has been demonstrated that dialysis treatment leads to increased rates of forearm phenylalanine uptake (proxy for 'muscle' protein synthesis) with an even greater rates of phenylalanine release (proxy for 'muscle' protein breakdown). Hence, the dialysis procedure itself is catabolic and induces a catabolic carryover for several hours after dialysis. This suggests prolonged post-dialysis disturbances in whole body- and skeletal muscle protein metabolism in MHD patients. Moreover, dialysis treatment in itself results in \~20 % losses of circulating amino acids in the dialysate. Collectively, this creates the need for replacement of amino acids by protein supplementation during and/or after dialysis. The ingestion of protein-dense meals in between dialysis treatments likely represents an important dietary strategy to counterbalance dialysis-induced catabolism and to achieve the current recommended protein intakes (set at 1.2 g/kg bodyweight/d) to limit muscle protein loss in MHD patients. However, the effectiveness of protein-rich meal ingestion to augment postprandial whole body and muscle protein metabolic responses in MHD patients outside of the dialysis period remain largely undefined. The purpose of this study is to compare basal and postprandial whole body leucine body kinetics, muscle anabolic sensing mechanisms, markers of muscle proteolysis, and myofibillar protein synthesis rates to mixed meal ingestion on a non-dialysis day in eight MHD patients, between 20-80 and to compare these outcomes to age- and BMI-matched controls. The investigators will use specifically produced intrinsically L-\[5,5,5-2H3\]leucine labeled eggs combined with primed constant amino acid tracer infusion methods and co
Primary Outcome
Measurement of muscle protein synthesis
Interventions
- OTHER Protein Meal
- OTHER Stable Isotope Amino Acid Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-01-18 |
| Est. Completion | 2018-04-01 |
What the finished NCT03478722 record still lists
NCT03478722 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Protein Meal is the first listed.
NCT03478722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03478722 about?
NCT03478722 is a clinical study titled "Muscle Protein Synthesis in Dialysis Patients". The most severe form of chronic renal failure is end-stage-renal-disease with maintenance hemodialysis (MHD) as the most common treatment strategy. MHD patients experience a number of metabolic and phenotypic derangements including skeletal muscle wasting. Previously, it has been demonstrated that d...
What is the current status of trial NCT03478722?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2017-01-18. Estimated completion is 2018-04-01.
What interventions are being tested in trial NCT03478722?
The interventions under investigation include: Protein Meal (OTHER), Stable Isotope Amino Acid Infusion (OTHER).
Who is sponsoring clinical trial NCT03478722?
This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI